Laboratory Compliance Under Increased Scrutiny
On August 28, 2026, the Centers for Medicare & Medicaid Services (CMS) announced that its enforcement actions prevented more than $1.6 billion in potentially improper Medicare laboratory payments. The results included $732 million in savings from revoking the Medicare enrollment of 157 laboratory providers; more than $500 million in potentially fraudulent payments halted through 185 payment suspensions following investigations of 600 laboratories; more than $276 million recovered from 442 identified overpayments; and $127 million in potentially fraudulent payments prevented through 85 referrals to law enforcement.
CMS attributed these results to program integrity initiatives that use advanced analytics, artificial intelligence, and machine-learning models to detect unusual billing patterns and other indicators of fraud, waste, or abuse before Medicare funds are disbursed. The announcement confirms that clinical laboratories remain an important enforcement focus for CMS, the U.S. Department of Justice (DOJ), and the U.S. Department of Health and Human Services Office of Inspector General (OIG). CMS specifically identified schemes involving medically unnecessary services, beneficiaries who had no established relationship with the ordering provider, services that were not rendered, and upcoded services.
Compliance officers should treat this development as a prompt to reassess whether their organizations’ compliance programs effectively address laboratory billing risks. Key areas include documentation of medical necessity, relationships with ordering providers, controls over test utilization, coding accuracy, claims review, timely identification and repayment of overpayments, sales and marketing practices, and internal auditing and monitoring.
Organizations should also consider engaging a qualified third party to conduct an independent evaluation of the compliance program. The evaluation should go beyond a checklist review and determine whether the organization has effective, evidence-based controls that can identify, investigate, and correct improper billing patterns before regulators do.
Interested in learning how Strategic Management can support your compliance program in light of evolving regulatory changes? Contact Richard Kusserow at [email protected].
